Methylprednisolone
Drug Category | Drug | IHD Dosing | Administration Timing Around HD Session |
---|---|---|---|
Immunosuppressants | Methylprednisolone | Normal dose based on indication | Administer Post-HD |
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
---|---|---|---|---|---|---|---|
374 | <10 | 3.17 | Unchanged | 40-60 | 1.2-1.5 | N/A | 5-20 (N/A) |
References:
- Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
- Bergrem, H. Pharmacokinetics and protein binding of prednisolone in patients with nephrotic syndrome and patients undergoing hemodialysis. Kidney International 1982; 23, 876-81.
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB00959